Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 219

Similar articles for PubMed (Select 23111865)

1.

Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.

Villacampa F, Ruiz MA, Errando C, Arlandis S, Arumí D, Lizarraga I, Rejas J.

Int Urogynecol J. 2013 Apr;24(4):573-81. doi: 10.1007/s00192-012-1921-x. Epub 2012 Oct 31.

PMID:
23111865
2.

Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.

Arlandis S, Ruiz MA, Errando C, Villacampa F, Arumí D, Lizarraga I, Rejas J.

Clin Drug Investig. 2012 Aug 1;32(8):523-32. doi: 10.2165/11633760-000000000-00000.

PMID:
22741748
3.

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.

Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.

BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.

PMID:
23826844
4.

A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden.

Peeker R, Samsioe G, Kowalski J, Andersson AS, Bergqvist A.

Scand J Urol Nephrol. 2010 Apr;44(3):138-46. doi: 10.3109/00365591003709468.

PMID:
20367449
5.

Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.

Kubota Y, Kojima Y, Shibata Y, Imura M, Kohri K, Sasaki S.

Neurourol Urodyn. 2011 Sep;30(7):1309-14. doi: 10.1002/nau.21065. Epub 2011 May 10.

PMID:
21560155
6.

Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.

Coyne KS, Elinoff V, Gordon DA, Deng DY, Brodsky M, Glasser DB, Jumadilova Z, Carlsson M.

Int J Clin Pract. 2008 Jun;62(6):925-31. doi: 10.1111/j.1742-1241.2008.01778.x.

PMID:
18479285
7.

[Spanish cultural adaptation and psychometrical validation of the Treatment Benefit Scale (TBS) in the symptomatic treatment of overactive bladder].

Errando-Smet C, Ruiz MA, Villacampa-Aubá F, Arlandis-Guzmán S, Rejas J, Ruiz L, García-Vargas M.

Med Clin (Barc). 2013 Jan 5;140(1):6-13. doi: 10.1016/j.medcli.2011.11.013. Epub 2012 Jan 16. Spanish.

PMID:
22257604
8.
9.

Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument.

Zinner N, Kobashi K, Koochaki P, Fix D, Egermark M.

Neurourol Urodyn. 2011 Jan;30(1):62-8. doi: 10.1002/nau.20890. Epub 2010 Sep 21.

PMID:
20860020
10.

Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.

Garely AD, Lucente V, Vapnek J, Smith N.

Ann Pharmacother. 2007 Mar;41(3):391-8. Epub 2007 Mar 6.

PMID:
17341526
11.

Do patient characteristics predict responsiveness to treatment of overactive bladder with antimuscarinic agents?

Herschorn S, Kaplan SA, Sun F, Ntanios F.

Urology. 2014 May;83(5):1023-9. doi: 10.1016/j.urology.2013.12.027. Epub 2014 Feb 26.

PMID:
24582119
12.

A comparison study of two lower urinary tract symptoms screening tools in clinical practice: the B-SAQ and OAB-V8 questionnaires.

Basra RK, Cortes E, Khullar V, Kelleher C.

J Obstet Gynaecol. 2012 Oct;32(7):666-71. doi: 10.3109/01443615.2012.696158.

PMID:
22943714
13.

Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.

Capo' JP Jr, Laramée C, Lucente V, Fakhoury A, Forero-Schwanhaeuser S.

Int J Clin Pract. 2008 Jan;62(1):39-46. Epub 2007 Nov 23.

PMID:
18036164
14.

Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.

Khullar V, Cardozo L, Kelleher CJ, Hall T, Ryan J, Ebel Bitoun C, Darekar A, Arumi D, Wagg A.

BJU Int. 2013 Oct;112(6):820-9. doi: 10.1111/bju.12006. Epub 2013 Mar 7.

PMID:
23465055
15.

Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.

Kelleher CJ, Dmochowski RR, Berriman S, Kopp ZS, Carlsson M.

BJU Int. 2012 Aug;110(3):392-400. doi: 10.1111/j.1464-410X.2011.10774.x. Epub 2011 Nov 30.

PMID:
22129365
16.

Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.

Kaplan SA, Roehrborn CG, Gong J, Sun F, Guan Z.

BJU Int. 2012 Jun;109(12):1831-40. doi: 10.1111/j.1464-410X.2011.10624.x. Epub 2011 Oct 3.

PMID:
21966995
17.

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.

Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.

PMID:
19601704
18.

Impact of symptom improvement on patients' bother and quality of life in female patients with overactive bladder treated by solifenacin (SET-Q).

Gotoh M, Kobayashi T, Sogabe K.

Int J Urol. 2014 May;21(5):505-11. doi: 10.1111/iju.12355. Epub 2013 Dec 5.

PMID:
24304092
19.
20.

Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.

Palleschi G, Pastore AL, Stocchi F, Bova G, Inghilleri M, Sigala S, Carbone A.

Clin Neuropharmacol. 2006 Jul-Aug;29(4):220-9.

PMID:
16855424
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk